Go Back
Nouscom
Backed by international life sciences investors, Nouscom was founded in 2015 and is headquartered in Basel, Switzerland. A clinical stage immuno-oncology company developing off-the-shelf and personalized cancer immunotherapies, Nouscom uses a proprietary viral vector platform which has the capacity to encode for large payloads of neoantigens to safely and potently harness the power of the immune system.
More Details
6 clinical trials are actively ongoing, including a randomized Phase 2 trial of NOUS-209 for the treatment of MSI-H solid tumors in combination with pembrolizumab, a Phase 1b ‘cancer interception’ in Lynch Syndrome as well as NOUS-PEV, a personalized cancer immunotherapy that will be reporting Phase 1 data at a forthcoming scientific conference in Q2 2023.
Nouscom has also exclusively out-licensed a third product, VAC-85135, to Janssen Oncology, which is currently under evaluation in a Phase 1 trial.